SEARCH RESULTS

Biotechnology in France

Anindita BANERJEE - 08-avr.-2014 12:23:15
  Even though biotechnologies may be a recent sector of business activity, France has succeeded in developing real know-how that is gaining international recognition. When it comes to biotechnologies, the French are cutting edge. According to Leeme, the federation of French medical companies, today France numbers 388 biotechs in the health field in France. Biotech France, another French association for biotech companies, indicates that a third of these companies have been in existence for over 10 years. Yet the number of creations in this field is exponential. To get an idea, 50 companies were started in 2012. Unheard of! Proof that there is a real entrepreneurial effervescence when it comes to this research in France. Young start-ups for the most part, French biotechs are mainly Small Medium sized companies. Only 4% of them have over 100 employees. On average, they employ 22 people. As to the type of activity, most of the French companies specialized in human sciences with therapeutic products are concentrated on cancer treatments. “The French have developed a full-fledged know-how on cardio-vascular devices, infectious diseases, dermatology, blood diseases and for surgery,” explains Yves Germani, Ubifrance’s manager for the health sector in North America. French enterprises don’t just do research; they discover! Altogether, the French biotech industry generated 261 Million Euros in turnover in 2011, compared with 186 Million in 2010. As for companies on the stock market, they generate 369 Million Euros in turnover. Concerning the pipeline, the expression used to indicate the number of molecules being developed, France is 4rth, behind the United Kingdom, Germany, Switzerland and Israel. Quite a solid ranking, but which should nevertheless be improved. When their results are examined in detail, we see that depending on the stage of development, French companies create more products in the pre-clinic phase, in other words, all those that have been carried out before the clinical trial with patients, which is completely logical. Between the start of development on a new medicine, a molecule and its release on the market can sometimes take up to 10 years. Unfortunately, the consequence of this is that a number of products fall by the wayside. To be noted, however, is one undeniable fact: since 2008, French companies have sold more and more products. To put it another way, as Yves Germani points out, French companies don’t just do research; they discover!” An increase of 63% in investment Even more impressive than all the rest, French biotech companies tend to have smaller R&D budgets than their European and international competitors. Fortunately, the culture of venture capital is developing very quickly in this sector. To give the general picture, the funds raised by French biotechs have increased by 63,1% from 2009 to 2012, reaching 178 Million Euros. Since the year 2000, they have managed to raise 2.920 Billion Euros. Today, French companies are naturally turning towards international opportunities to find new partners and new financial leverage. The proof is that such Small Medium companies as Affilogic, MedinCell, Interactive Biosoftware, Imabiotech or even O4CP all have one thing in common: they all are reaching out with confidence to mature markets like the United States, Canada and Western Europe.  

Sanofi files cases against Glenmark on patent infringement

Nathalie OSTERNAUD - 12-mars-2014 07:22:18
Hyderabad, March 5th,  French drug-maker Sanofi filed patent infringement petition against Glenmark on cardiac drug Multaq, in the district court of Delaware, on three counts. According to the petition, the Indian drug maker had submitted its application to seek US Food and Drug Administration’s (USFDA’s) approval for its generic version of the drug on January 24, 2014. Sanofi and Sanofi-Aventis US LLC filed the suit against Glenmark and Dublin-based Actavis (Watson) on February 26, 2014 in the US court seeking to prevent the duo from commercialising its ANDA product prior to the expiration of certain US patents. The lawsuit was filed under the provisions of the Hatch- Waxman Act, resulting in a stay on final FDA approval of Actavis’ ANDA until Jan 1, 2017, or final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities. Multaq, is an anti-arrhythmic drug indicated to reduce the risk of hospitalisation for atrial fibrillation (AF) in patients in sinus rhythm with a history of paroxysmal or persistent AF. For the 12 months ending December 31, 2013, Multaq had total US sales of approximately USD 319 million, according to IMS Health data. Actavis is most likely to get the 180 days exclusivity of the drug. However, based on the outcome of the court and FDA approval, if Glenmark negotiates successfully they may get shared exclusivity, Dalal said. A first-to-file status on generic application allows the generic drug firm 180 days of marketing exclusivity after the innovator patent expiry. Source PTI
About
Sophie Clavelier, Country Head   Welcome to the French Trade Commission Business France in India!     Our key mission is to promote trade relations between France and India. We assist French- based companies seeking potential partners and new markets in India, while helping Indian businesses to identify potential French suppliers, commercial and technical partners.   In India, our 4 offices are located in business hubs, New Delhi, Mumbai, Bengaluru and Chennai. We have a dedicated multicultural team of 38 experts in the following growing sectors: Agrofood Industry Industry and Cleantech Lifestyle and Healthcare Tech & Services Our Trade Commission also has a Press office in charge of helping French companies to communicate in India as well as a Market Access Department enabling them to better understand and adjust to the Indian regulatory and fiscal framework. In

READ MORE

Facebook
Press area & Media Gallery
List of last comments

Bluestorage is a subsidiary of the Bollo...

Malcolm MESSIER | février 22, 2019

AdBGQi Thank you for this impressive rep...

best pron | janvier 29, 2018

pYktcT Well I definitely liked studying ...

just another | novembre 08, 2017

dv1KAR Say, you got a nice post.Thanks A...

best pron | septembre 20, 2017